-
Natera IPO Offers New Non-Invasive Prenatal Procedure
Thursday, July 2, 2015 - 1:23pm | 866Read More...Natera Inc (NASDAQ: NTRA), a provider of genetic testing services, looks to raise $100 million in its IPO Thursday. Natera priced 10 million shares at $18. The company will list on the NASDAQ under the ticker NTRA. Diagnostic companies going public have been met with mixed feelings. Based in...
-
Sony and Illumina Set to Change the Way Doctors Identify and Treat Cancer (ILMN, SNE)
Thursday, September 5, 2013 - 2:55pm | 519Read More...In a story first reported by Nikkei and updated recently by Le Monde, Sony Corp. (NYSE: SNE) and U.S. genome sequencing equipment maker Illumina Inc. (NASDAQ: ILMN) plan to launch a human genome analysis project in October. The project will involve the study and analysis of genetic material...
-
Piper Jaffray Maintains Rating, Ups PT On Illumina To $79
Friday, April 8, 2011 - 7:26am | 103Read More...Piper Jaffray is maintaining its Overweight rating and has upped its price target on Illumina Inc. (NASDAQ: ILMN) from $76 to $79 based on analysis. In the report, Piper Jaffray states, “We recently updated our proprietary sequencing database which tracks Illumina and competing sequencing...
-
Piper Jaffray Raises PT On Illumina To $79
Friday, April 8, 2011 - 6:53am | 26Read More...Piper Jaffray has raised the price target on Illumina (NASDAQ: ILMN) from $76 to $79 and maintains its Overweight rating.
-
Auriga Upgrades Illumina To Buy, $75 PT
Monday, March 28, 2011 - 7:23am | 25Read More...Auriga USA has upgraded Illumina Inc. (NASDAQ: ILMN) from Neutral to Buy and reiterates its $75 price target.
-
Piper Jaffray Provides Color On ILMN Leukemia Tumor Data
Monday, February 7, 2011 - 9:19am | 145Read More...Data from Illumina, Inc. (NASDAQ: ILMN) in leukemia tumors after deep re-sequencing found a class of mutations that were not present with the initial diagnosis, Piper Jaffray reports. “If this work is reproduced in other cancer types where we had initially expected 2-3 sequencing runs, (normal,...
-
Illumina Inc (ILMN) Maintains Buy Rating
Tuesday, November 9, 2010 - 8:54am | 62Read More...Goldman Sachs published its research report on Illumina Inc (NASDAQGS: ILMN) this morning in which they maintain a Buy rating. Analysts note a lack of "material changes" as to why there are no changes in the investment thesis, rating, or price target. Goldman Sachs set the price target at $65.00....
